Of the 103 patients who completed the Phase III trial, more than half saw remission from a drug-induced condition.

Biotech and biopharma companies have battled with a drought of private investment in recent years but could now face government funding cuts.

NACE has collaborated with 17 Australian general practices and allergy clinics to launch the ARISE trial for young people with hay fever.

Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...

Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.

AstraZeneca acquired the hypoparathyroidism therapy eneboparatide as part of a buyout of Amolyt Pharma in July 2024.

The company plans to submit a Biologics Licence Application to the US Food and Drug Administration later in 2025 for its DMD ...

Orca Bio’s T-cell immunotherapy candidate for blood cancers has more than doubled the number of patients surviving free of ...

Evinova has partnered with QLHC to incorporate its RPM solution into the I-SPY 2.2 trial of various breast cancer treatments.

AbbVie has reported analysis from a Phase III trial that assessed Elahere against chemotherapy for platinum-resistant ovarian ...

The United States is experiencing a multi-state measles outbreak, resulting in the highest case spike since 2019.